471 patents
Page 9 of 24
Utility
ANTI-AVBETA8 Antibodies and Compositions and Uses Thereof
15 Sep 22
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to αvβ8 integrin.
Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
Filed: 13 May 22
Utility
Toll-like Receptor Agonists
1 Sep 22
The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
Omar Ahmad, Andrew Fensome, Erik Alphie LaChapelle, Ethan Lawrence Fisher, Rayomand J. Unwalla, Jun Xiao, Lei Zhang
Filed: 6 May 22
Utility
Nitrile-Containing Antiviral Compounds
18 Aug 22
Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
Filed: 22 Apr 22
Utility
Methods of Treating Neurofibromatosis with N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHENYLAMINO)-BENZAMIDE
18 Aug 22
The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier; and c) methods of treating a tumor, a cancer, or a Rasopathy disorder by administering the crystalline composition of essentially pure Form IV of N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof.
Erwin IRDAM
Filed: 24 Jun 21
Utility
Sulfonyl Amide Derivatives for the Treatment of Abnormal Cell Growth
11 Aug 22
Michael Joseph Luzzio, Kevin Daniel Freeman-Cook, Samit Kumar Bhattacharya, Matthew Merrill Hayward, Catherine Angela Hulford, Christopher Lowell Autry, Xumiao Zhao, Jun Xiao, Kendra Louise Nelson
Filed: 27 Aug 21
Utility
Protein Tyrosine Phosphatase Inhibitors
11 Aug 22
James Francis BLAKE, Mark Laurence BOYS, Mark Joseph CHICARELLI, Adam Wade COOK, Mohamed S. A. ELSAYED, Jay Bradford FELL, John P. FISCHER, Ronald Jay HINKLIN, Yutong JIANG, Oren Teague MCNULTY, Macedonio J. MEJIA, Martha E. RODRIGUEZ, Christina Elizabeth WONG
Filed: 13 Apr 22
Utility
Cycloalkyl and Heterocycloalkyl Benzisoxazole Sulfonamide Derivatives
11 Aug 22
Oleg Brodsky, Samantha Elizabeth Greasley, Robert Louis Hoffman, Pei-Pei Kung, Paul Francis Richardson, Paul Anthony Stupple
Filed: 17 Jun 20
Utility
PD-1 Axis Binding Antagonist to Treat Cancer with Genetic Mutations In Specific Genes
4 Aug 22
The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers.
Marat Alimzhanov, Keith Anthony Ching, Alessandra Di Pietro, Xinmeng Mu, Paul Brian Robbins
Filed: 29 May 20
Utility
Combination Therapies Using CDK Inhibitors
4 Aug 22
This invention relates to a method for treating cancer by administering a CDK4/6 or a CDK2/4/6 inhibitor in combination with a PD-1 axis binding antagonist, and optionally an OX40 agonist and/or a 4-1BB agonist to a subject in need thereof.
Stephen George Dann, Cecilia Marianne Oderup, Shahram Salek-Ardakani
Filed: 20 May 20
Utility
Combination Therapies Using CDK Inhibitors
28 Jul 22
This invention relates to a method for treating cancer by administering a CDK4/6 inhibitor or CDK2/4/6 inhibitor in combination with a 4-1BB agonist and/or an OX40 agonist to a subject in need thereof.
Stephen George Dann, Cecilia Marianne Oderup, Shahram Salek-Ardakani
Filed: 21 May 20
Utility
Hydroxylated and Methoxylated Pyrimidyl Cyclopentanes As Akt Protein Kinase Inhibitors
21 Jul 22
Ian S. Mitchell, James F. Blake, Rui Xu, Nicholas C. Kallan, Dengming Xiao, Keith Lee Spencer, Josef R. Bencsik, Eli M. Wallace, Stephen T. Schlachter, Anna L. Leivers, Jun Liang, Brian Safina, Birong Zhang, Christine Chabot, Steven Do
Filed: 23 Aug 21
Utility
Protease-activating CD45-GATE Car
21 Jul 22
A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain.
Shanshan LANG, Thomas John VAN BLARCOM, Michael Thomas BETHUNE, Siler PANOWSKI, Nguyen TAN, Yi ZHANG, Barbra Johnson SASU, Zhe LI
Filed: 21 Dec 21
Utility
Chimeric Antigen Receptors Targeting Epidermal Growth Factor Receptor Variant III
21 Jul 22
The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III).
Oi Kwan Wong, Joyce Ching Chou, Mathilde Brunnhilde Dusseaux, Julianne Smith, Barbra Johnson Sasu
Filed: 27 Jan 22
Utility
Dosing Regimen of Avelumab for the Treatment of Cancer
14 Jul 22
The present invention relates to dosing regimen of avelumab for the treatment of cancer.
Glen Ian Andrews, Carlo Leonel BELLO, Satjit Singh BRAR, Shaonan WANG, Pascal GIRARD
Filed: 9 Feb 22
Utility
E. Coli Fimh Mutants and Uses Thereof
30 Jun 22
This disclosure relates to the design of E. coli mutated FimH polypeptides that result in improved biochemical properties and immunogenicity, compositions comprising such polypeptides, and uses thereof.
Ye Che, Laurent Oliver Chorro, Robert George Konrad Donald, Matthew Curtis Griffor, Natalie Clare Silmon de Monerri
Filed: 17 Dec 21
Utility
Real-time Tracking and Management of Standard Workflows
30 Jun 22
Lean manufacturing principles are integrated into computing components for the generation, collection, analysis, and propagation of real-time manufacturing and supply operations data.
Michael P. CAREY, Matthew Brian ELK, Maxwell Noah GOTT, René LEHOUX, Kailin Haley MACINTYRE, David Scott MCGETTIGAN, John Paul MCTERNAN, Jefferey Maurice MOORE, Cian O'MEARA, Sara Tali OPPENHEIMER, Michael Henry TOMASCO, Yiming XIAO
Filed: 30 Apr 20
Utility
Metabolites of GLP1R Agonists
23 Jun 22
The present invention provides metabolites of Compound 1 or a compound of Formula I or III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I or III.
Andrew John Bessire, David James Edmonds, David Andrew Griffith, Amit Sumant Kalgutkar
Filed: 9 Dec 21
Utility
(AZA)Benzothiazolyl Substituted Pyrazole Compounds
16 Jun 22
Shawn Cabral, Daniel Paul Canterbury, Robert Lee Dow, Andrew Fensome, Magdalena Korczynska, Sophie Yvette Lavergne, Allyn Timothy Londregan, Vincent Mascitti, David Walter Piotrowski, Andre Shavnya, Meihua Mike Tu, Tao Wang, Hanna Maria Wisniewska
Filed: 23 Nov 21
Utility
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens, Kits Comprising the Same and Uses Thereof
16 Jun 22
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof.
Annaliesa Sybil Anderson, Isis Kanevsky, Farid Latif Khan, Charles Harold Jones, John Michael McLaughlin
Filed: 6 Apr 20
Utility
Stable Liquid Antibody Formulation
9 Jun 22
The present invention relates generally to the field of pharmaceutical formulations of antibodies.
Advait Vijay Badkar, Leigh Kristen Bohack, Kevin Roger King, Alanta Lea Lary
Filed: 16 Jul 21